Sponsored Links
| Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease |
 |
 |
 |
| Medical News - Huntingtons Disease | |||
|
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. The international safety and efficacy trial, known as HORIZON, is designed to evaluate the potential benefits of dimebon on cognition (thinking and memory) in patients with Huntington disease. The companies also announced that the U.S. Read more: Huntingtons Disease News From Medical News Today
|